Skip to main content

Table 3 Distribution of C4 polymorphisms in Graves' disease patients with or without myxedema

From: Association between copy number variation of complement component C4 and Graves' disease

Variations Myxedema P value, individuala
[OR (95%CI), individual]c
P valueb OR (95%CI)d
  No, N (%) Yes, N (%)    
C4 CNV      
4 265 (50.5) 48 (49.0) 0.826   (Reference)
< 4 100 (19.0) 34 (34.7) 0.001 [1.884 (0.538-6.597)] 4.900 × 10-4 1.714 (0.447-6.575)
> 4 160 (30.5) 16 (16.3) 0.005 [0.617 (0.166-2.289)]   0.761 (0.186-3.122)
C4A CNV      
2 336 (64.0) 58 (59.2) 0.364   (Reference)
< 2 57 (10.9) 22 (22.5) 0.003 [0.627 (0.164-2.404)] 0.008 0.511 (0.122-2.134)
> 2 132 (25.1) 18 (18.4) 0.159   0.496 (0.117-2.106)
C4B CNV      
2 317 (60.4) 59 (60.2) 1   (Reference)
< 2 115 (21.9) 28 (28.6) 0.152 0.168 1.163 (0.298-4.542)
> 2 93 (17.7) 11 (11.2) 0.072   0.552 (0.125-2.443)
C4 polymorphisms      
A2B2 217 (41.3) 36 (36.7) 0.434 0.050 (Reference)
A2B1 63 (12.0) 15 (15.3) 0.405   1.895 (0.307-11.710)
A3B2 58 (11.0) 6 (6.1) 0.202   1.371 (0.163-11.522)
A2B3 41 (7.8) 3 (3.1) 0.130   0.558 (0.029-10.789)
A3B1 26 (5.0) 6 (6.1) 0.619   0.333 (0.032-3.499)
A1B2 23 (4.4) 11 (11.2) 0.013 [1.094 (0.137-8.709)]   1.009 (0.103-9.841)
Other 97 (18.5) 21 (21.4)    0.735 (0.163-3.310)
  1. Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
  2. aIndividual C4 CNVs and polymorphisms between GD patients with or without myxedema were evaluated by Fisher's exact test using 2 × 2 contingency tables.
  3. b CNV of C4, C4A and C4B between GD patients with or without myxedema were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without myxedema were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
  4. cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.
  5. dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.